Marquette Asset Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Marquette Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,410	Closed	-$114K	–	244
2022 Q3	$114K	Hold	2,410	–	–	0.04%	98
2022 Q2	$104K	Buy	2,410 +579	+32%	+$26.6K	0.03%	127
2022 Q1	$101K	Buy	1,831 +371	+25%	+$20.8K	0.02%	146
2021 Q4	$111K	Buy	1,460 +495	+51%	+$38.9K	0.02%	143
2021 Q3	$87K	Buy	+965	New	+$103K	0.02%	150

Other funds holding DMRA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marquette Asset Management's DMRA Position: Q4 2022 in Review

Marquette Asset Management sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q4 2022, closing a stake of 2,410 shares — an estimated $114K sold.

Marquette Asset Management first reported a position in DMRA in Q3 2021 and held it in 5 quarters. The position peaked at $114K in Q3 2022. 22 funds tracked by Wall St. Rank hold DMRA as of Q4 2022.

Marquette Asset Management reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Marquette Asset Management sold 2,410 Damora Therapeutics, Inc. Ordinary Shares shares in Q4 2022, an estimated $114K.
Marquette Asset Management first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q3 2021 and held it in 5 quarters.
Marquette Asset Management's Damora Therapeutics, Inc. Ordinary Shares position peaked at $114K in Q3 2022.
22 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q4 2022.

Based on Marquette Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.